A worldwide, exclusive license is being granted to develop and commercialize enzyme replacement therapies using proprietary platform technology.
At AAPS PharmSci 360 2025, Elly Zhou says digital twins helped forecast the effects of drugs on human drugs via a digital control arm.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback